O. Efremenkova, I. A. Malanicheva, B. Vasileva, T. A. Efimenko, A. A. Glukhova, O. Kisil, M. V. Demiankova, H. S. Semizaev, N. Gabrielyan
{"title":"Induction and Stabilization of Antibacterial Activity in a Bacillus subtilis 534 Probiotic Strain","authors":"O. Efremenkova, I. A. Malanicheva, B. Vasileva, T. A. Efimenko, A. A. Glukhova, O. Kisil, M. V. Demiankova, H. S. Semizaev, N. Gabrielyan","doi":"10.37489/0235-2990-2022-67-9-10-4-10","DOIUrl":null,"url":null,"abstract":"Medicinal probiotic Sporobacterin is based on the Bacillus subtilis 534 strain, which has been shown to have antimicrobial activity against many bacteria, both the collection strains and the antibiotic-resistant forms of clinical isolates of pathogenic bacteria and fungi. Considering this strain as an antibiotic producer, a step-by-step mutagenic treatment was carried out in order to obtain a variant that consistently exhibits a certain high-level antibiotic activity. A mutant variant was obtained during the three stages of mutagenic treatment and selection; it effectively suppresses the growth of pathogenic staphylococci, including methicillin-resistant staphylococcus (MRSA).","PeriodicalId":8471,"journal":{"name":"Antibiotics and Chemotherapy","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2022-12-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Antibiotics and Chemotherapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.37489/0235-2990-2022-67-9-10-4-10","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Medicinal probiotic Sporobacterin is based on the Bacillus subtilis 534 strain, which has been shown to have antimicrobial activity against many bacteria, both the collection strains and the antibiotic-resistant forms of clinical isolates of pathogenic bacteria and fungi. Considering this strain as an antibiotic producer, a step-by-step mutagenic treatment was carried out in order to obtain a variant that consistently exhibits a certain high-level antibiotic activity. A mutant variant was obtained during the three stages of mutagenic treatment and selection; it effectively suppresses the growth of pathogenic staphylococci, including methicillin-resistant staphylococcus (MRSA).